Top

Supportive Care in Cancer

Published in:

01-08-2015 | Original Article

Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome

Authors: Lesley Stafford, Fiona Judd, Penny Gibson, Angela Komiti, G. Bruce Mann, Michael Quinn

Published in: Supportive Care in Cancer | Issue 8/2015

Abstract

Purpose

The purposes of this study are to examine the course and prevalence of anxiety and depression over 24 months in women with newly diagnosed breast and gynaecologic cancer and, controlling for demographic and clinical confounders, to test the role of neuroticism and psychiatric history in determining outcome 6, 12, 18 and 24 months post-diagnosis.

Methods

Participants completed the Hospital Anxiety and Depression Scale—anxiety subscale and Centre for Epidemiological Studies Depression Scale on an 8-weekly basis from diagnosis until 96 weeks. Changes over time were analyzed with repeated measures ANOVA. Hierarchical linear regression, adjusted a priori for age, chemotherapy and radiation treatment, living alone, education and tumour stream were used to predict anxiety and depression.

Results

Participants were 105 women (66 breast, 39 gynaecologic). Rates of anxiety (18.1 %) and depression (33.3 %) were highest at diagnosis. Average rates of anxiety and depression were 5.9 and 22.4 %, respectively. Average scores of anxiety and depression were highest at diagnosis, with improvement at 8 and 40 weeks, respectively, subsequently maintained. Morbidity at diagnosis was particularly acute among women with a treatment history of anxiety/depression or with high neuroticism. These three variables were the best and only predictors over 24 months.

Conclusions

Women are most vulnerable to anxiety and depression at diagnosis, with improvement over time. Morbidity rates are lower than reported elsewhere. Women with high neuroticism and a psychiatric history are at greatest risk for future morbidity after adjusting for confounders. Early identification of these women plus heightened surveillance or early referral to psychosocial services may protect against longer-term morbidity.

Australian Institute of Health (2012) Cancer in Australia: an overview 2012. AIHW, Canberra

Fallowfield L, Ratcliffe D, Jenkins V, Saul J (2001) Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 84:1011–1015PubMedCentralPubMedCrossRef

Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psycho-Oncology 10:19–28PubMedCrossRef

Fowler JM, Carpenter KM, Gupta P, Golden-Kreutz DM, Andersen BL (2004) The gynecologic oncology consult: symptom presentation and concurrent symptoms of depression and anxiety. Obstet Gynecol 103:1211–1217PubMedCentralPubMedCrossRef

van Amstel FK P, van den Berg SW, van Laarhoven HW, Gielissen MF, Prins JB, Ottevanger PB (2013) Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer 21:2107–2115CrossRef

Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J (2009) Predictors of depressive symptoms 12 months after surgical treatment of early-stage breast cancer. Psycho-Oncology 18:1230–1237CrossRef

Manne S, Rini C, Rubin S, Rosenblum N, Bergman C, Edelson M et al (2008) Long-term trajectories of psychological adaptation among women diagnosed with gynecological cancers. Psychosom Med 70:677–687PubMedCrossRef

Stafford L, Judd F, Gibson P, Komiti A, Mann G, Quinn M (2013) Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psycho-Oncology 22:2071–2078PubMedCrossRef

Lindviksmoen G, Hofso K, Paul SM, Miaskowski C, Rustoen T (2013) Predictors of initial levels and trajectories of depressive symptoms in women with breast cancer undergoing radiation therapy. Cancer Nurs 36:E34–E43PubMedCrossRef

10.

Johnson RL, Gold MA, Wyche KF (2010) Distress in women with gynecologic cancer. Psycho-Oncology 19:665–668PubMedCrossRef

11.

Enns A, Waller A, Groff SL, Bultz BD, Fung T, Carlson LE (2013) Risk factors for continuous distress over a 12-month period in newly diagnosed cancer outpatients. J Psychosoc Oncol 31:489–506PubMedCrossRef

12.

Torres MA, Pace TW, Liu T, Felger JC, Mister D, Doho GH et al (2013) Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer 119:1951–1959PubMedCentralPubMedCrossRef

13.

Iwatani T, Matsuda A, Kawabata H, Miura D, Matsushima E (2013) Predictive factors for psychological distress related to diagnosis of breast cancer. Psycho-Oncology 22:523–529PubMedCrossRef

14.

Hulbert-Williams L, Neal RD, Morrison V, Hood K, Wilkinson C (2012) Anxiety, depression and quality of life after cancer diagnosis: what psychosocial variables best predict how patients adjust? Psycho-Oncology 21:857–867PubMedCrossRef

15.

Wong-Kim E, Bloom J (2005) Depression experienced by young women newly diagnosed with breast cancer. Psycho-Oncology 14:564–573PubMedCrossRef

16.

Kim JM, Jang JE, Stewart R, Kim SY, Kim SW, Kang HJ et al (2013) Determinants of suicidal ideation in patients with breast cancer. Psycho-Oncology 22:2848–2856PubMedCrossRef

17.

Van Esch L, Roukema JA, Ernst MF, Nieuwenhuijzen GA, De Vries J (2012) Combined anxiety and depressive symptoms before diagnosis of breast cancer. J Affect Disord 136:895–901PubMedCrossRef

18.

Osborn R, Demoncada A, Feuerstein M (2006) Psychosocial interventions for depression, anxiety and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 36:13–34PubMedCrossRef

19.

Weiss A, Costa PT Jr (2005) Domain and facet personality predictors of all-cause mortality among Medicare patients aged 65 to 100. Psychosom Med 67:724–733PubMedCrossRef

20.

Watson D, Pennebaker J (1989) Health complaints, stress and distress: exploring the central role of negative affectivity. Psychol Rev 96:234–254PubMedCrossRef

21.

Krueger R, Caspi A, Moffitt T, Silva P, McGee R (1996) Personality traits are differentially linked to mental disorders: a multi-trait multi-diagnosis study of an adolescent birth cohort. J Abnorm Psychol 105:299–312PubMedCrossRef

22.

Scott J, Eccleston D, Boys R (1992) Can we predict the persistence of depression? Br J Psychiatry 161:633–637PubMedCrossRef

23.

Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef

24.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52:69–77PubMedCrossRef

25.

Radloff LS (1977) The CESD scale: a self report scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef

26.

Mitchell AJ, Meader N, Davies E, Clover K, Carter GL, Loscalzo MJ et al (2012) Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group. J Affect Disord 140:149–160PubMedCrossRef

27.

Luckett T, Butow PN, King MT, Oguchi M, Heading G, Hackl NA et al (2010) A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses. Support Care Cancer 18:1241–1262PubMedCrossRef

28.

Mulrow C, William J, Gerety M, Ramirez G, Montiel O, Kerber C (1995) Case-finding instruments for depression in primary care settings. Ann Intern Med 122:913–921PubMedCrossRef

29.

Goldberg L (2001) International personality item pool. www.ipip.ori.org

30.

Gow A, Whiteman M, Pattie A, Deary I (2005) Goldberg’s ‘IPIP’ Big-Five factor markers: internal consistency and concurrent validation in Scotland. Personal Individ Differ 39:317–329CrossRef

31.

Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191PubMedCrossRef

32.

Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S et al (2012) Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol 124:389–394PubMedCrossRef

33.

Hoey LM, Ieropoli SC, White VM, Jefford M (2008) Systematic review of peer-support programs for people with cancer. Patient Educ Couns 70:315–337PubMedCrossRef

34.

Hartl K, Engel J, Herschbach P, Reinecker H, Sommer H, Friese K (2010) Personality traits and psychosocial stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psycho-Oncology 19:160–169PubMedCrossRef

35.

Linden W, Girgis A (2012) Psychological treatment outcomes for cancer patients: what do meta-analyses tell us about distress reduction? Psycho-Oncology 21:343–350PubMedCrossRef

36.

Greer J, Pirl W, Park E, Lynch TJ, Temel J (2008) Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res 65:549–552PubMedCentralPubMedCrossRef

37.

Carlson LE, Bultz BD Benefits of psychosocial oncology care: improved quality of life and medical cost offset. Health Qual Life Outcomes 1:8

38.

Satin J, Linden W, Phillips M (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349–5361PubMedCrossRef

39.

Cuijpers P, Smit F, Penninx BW, de Graaf R, ten Have M, Beekman AT (2010) Economic costs of neuroticism: a population-based study. Arch Gen Psychiatry 67:1086–1093PubMedCrossRef

40.

Tamagawa R, Garland S, Vaska M, Carlson LE (2012) Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome. J Behav Med 35:658–673PubMedCrossRef

41.

Nakaya N, Hansen PE, Schapiro IR, Eplov LF, Saito-Nakaya K, Uchitomi Y et al (2006) Personality traits and cancer survival: a Danish cohort study. Br J Cancer 95:146–152PubMedCentralPubMedCrossRef

42.

Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG et al (2000) Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36:1488–1497PubMedCrossRef

Title: Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome
Authors: Lesley Stafford
Fiona Judd
Penny Gibson
Angela Komiti
G. Bruce Mann
Michael Quinn
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 8/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2571-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2015

Is there a role for survivorship care plans in advanced cancer?

A systematic review on the use of exercise interventions for individuals with myeloid leukemia

Efficacy of a brief nurse-led pilot psychosocial intervention for newly diagnosed Asian cancer patients

Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS)

Successful use of central venous catheters in the management of recurrent malignant pleural effusions: one new option

Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer